Evidence map›Paper›PMID 34702264›Full record

ArticleRespiratory research2021

The lung microbiome in end-stage Lymphangioleiomyomatosis.

Julie Ng, Gustavo Pacheco-Rodriguez, Lesa Begley, Yvonne J Huang, Sergio Poli, Mark A Perrella, Ivan O Rosas, Joel Moss, Souheil El-Chemaly

Open access · goldAbstract readComparative StudyLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Respiratory research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 83% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 1 country.

Julie NgDepartment of Medicine, Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA, 02115, USA.
Gustavo Pacheco-Rodriguez *Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Lesa Begley *Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI, USA.
Yvonne J HuangDepartment of Medicine, Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI, USA.
Sergio PoliDepartment of Medicine, Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA, 02115, USA.
Mark A PerrellaDepartment of Medicine, Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA, 02115, USA.
Ivan O RosasDepartment of Medicine, Section of Pulmonary and Critical Care Medicine, Baylor College of Medicine, Houston, TX, USA.
Joel MossPulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Souheil El-ChemalyDepartment of Medicine, Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA, 02115, USA. Sel-chemaly@bwh.harvard.edu.
Harvard University · USUniversity of Michigan–Ann Arbor · USBaylor College of Medicine · USMount Sinai Medical Center · USNational Heart Lung and Blood Institute · USNational Institutes of Health · US

Funding

RESPIRATORY RESEARCHT32HL007633 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI George R Washko · 1985 to 2026
$14.9M
Sputum Microbial Markers of Type 2-Low AsthmaR01AI129958 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI HUANG, YVONNE JEAN · 2017 to 2021
$3.6M
NHLBI NIH HHS T32 HL007633NIAID NIH HHS R01 AI129958NIH HHS T32HL007633
6 · The paper itself

Abstract

Lymphangioleiomyomatosis (LAM) is a progressive cystic lung disease with mortality driven primarily by respiratory failure. Patients with LAM frequently have respiratory infections, suggestive of a dysregulated microbiome. Here we demonstrate that end-stage LAM patients have a distinct microbiome signature compared to patients with end-stage chronic obstructive pulmonary disease.

Indexed as

MicrobiotaDisease ProgressionDysbiosisHumansLungLung Diseases, FungalLymphangioleiomyomatosisPulmonary Disease, Chronic ObstructiveRespiratory Tract InfectionsRibotypingLymphangioleiomyomatosisMicrobiome

Identifiers

PMID34702264
PMCPMC8549264
OpenAlexW3208372427

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.